Precision Oncology

What is Personalised, Precision or Stratified
Medicine?

“an innovative approach to tailoring disease prevention and treatment that takes into account differences in people's genes, environments, and lifestyles” - FDA

“a move away from a one size fits all approach to … target therapies to achieve the best outcomes in the management of a patient” - NHS

“medical decisions, practices, interventions and/or products … tailored to the individual patient” - Wikipedia

Physiomics is Uniquely Positioned to Support
the Personalised Treatment of Cancer

Physiomics is working on a number of projects focused on supporting the personalised treatment of cancer. We believe we have a unique combination of capabilities that support our work in this field.

Knowledge of Cancer

Accessing and Curating Data

Population PK/PD Modelling

AI Machine Learning

Discover Physiomics’ Innovative Tool for the Personalised Treatment of Cancer

For its first personalised oncology tool, Physiomics has focused on developing a tool for the personalization of docetaxel dosing in late stage prostate cancer.

If it were to be approved by regulatory authorities, the personalised dosing tool could potentially achieve the following benefits without significantly disrupting the current clinical treatment pathway:

Improve Patient Outcomes

Substantially reduce the occurrence of both under-dosing and over-dosing, leading to improved patient outcomes

Reduce Costs

Reduce costs associated with toxicity-related interventions and drug waste

Minimise Subsequent Expensive Treatments

It can also help postpone the need for subsequent expensive lines of treatment.

Personalised Dosing Tool Overview

Prostate cancer annual incidence 50k in UK, 170k in US
10-20% present with late stage metastatic disease (5 yrsurvival <30%)
Late stage disease typically treated with docetaxel (3 weekly cycles until progression)

Effective ‘underdosing’ and ‘overdosing’ of docetaxel common due to inter-patient variability
Potentially leads to either lack of efficacy or increased toxicity
Wastes healthcare resources and increases costs

We have developed a tool to help physicians understand the effect of the drug in specific patients and enable them to see the possible effect of changing dose
Current personalised-dosing tools typically require costly additional assays and do not provide insight into toxicity or efficacy.

Personalised Dosing Tool Development

Data Identification

Identified public domain data on treatment of prostate cancer using docetaxel for 400+ patients from the comparator arm of a clinical trial

AI & Machine Learning

Applied AI techniques such as neural networks and other machine learning approaches to identify key factors linking dose, toxicity and efficacy

Web-Based Tool

Developed a web-based tool that could, if approved, form the basis of a decision support system for clinicians treating patients with prostate cancer to help reduce cost of toxicity and improve outcomes for patients.

Interested in collaborating with us?

We’ll arrange a brief consultation for you with a specialist in our team.

SET UP CONSULTATION